Pharmacotherapy of Alcohol Use Disorders by the Veterans Health Administration: Patterns of Receipt and Persistence
- 1 July 2012
- journal article
- Published by American Psychiatric Association Publishing in Psychiatric Services
- Vol. 63 (7) , 679-685
Abstract
This study assessed changes since 2007 at Veterans Health Administration (VHA) facilities (N=129) in use of the medications approved by the U.S. Food and Drug Administration for treatment of alcohol use disorders. VHA data from fiscal years (FYs) 2008 and 2009 were used to identify patients with a diagnosis of an alcohol use disorder who received oral or extended-release naltrexone, disulfiram, or acamprosate as well as the proportion of days covered (PDC) in the 180 days after initiation and the time to first ten-day gap in possession (persistence) for each medication. Multilevel, mixed-effects logistic regression models examined the association between patient and facility characteristics and use of medications. Nationally, 3.4% of VHA patients with an alcohol use disorder received medications in FY 2009 (11,165 of 331,635 patients), up from 3.0% in FY 2007. Use of medications by patients at the facilities ranged from 0% to 12%. In fully adjusted analyses, facilities offering evening and weekend services had higher rates of medication receipt, but other facility characteristics, such as having prescribers on the addiction program's staff or using medication to treat opioid or tobacco dependence, were unrelated to medication receipt. The mean PDC of acamprosate was significantly lower than mean PDCs of the other medications (p<.05), and persistence in use of naltrexone was significantly greater than use of acamprosate and significantly less than use of disulfiram (p<.05). Use of these medications is increasing but remains variable across the VHA system. Interventions are needed to optimize initiation of and persistence in use of these medications.Keywords
This publication has 13 references indexed in Scilit:
- Alcohol and opioid dependence medications: Prescription trends, overall and by physician specialtyDrug and Alcohol Dependence, 2009
- Persistence with oral naltrexone for alcohol treatment: implications for health‐care utilizationAddiction, 2008
- Medication Compliance and Persistence: Terminology and DefinitionsValue in Health, 2008
- What Role Does Measuring Medication Compliance Play in Evaluating the Efficacy of Naltrexone?Alcohol, Clinical and Experimental Research, 2007
- Transition to the new race/ethnicity data collection standards in the Department of Veterans AffairsPopulation Health Metrics, 2006
- Measurement of Adherence in Pharmacy Administrative Databases: A Proposal for Standard Definitions and Preferred MeasuresAnnals of Pharmacotherapy, 2006
- Patterns of Dispensed Disulfiram and Naltrexone for Alcoholism Treatment in a Veteran Patient PopulationAlcohol, Clinical and Experimental Research, 2004
- Datapoints: Trends in Naltrexone Use Among Members of a Large Private Health PlanPsychiatric Services, 2004
- Agreement Between Administrative Data and Patients’ Self-Reports of Race/EthnicityAmerican Journal of Public Health, 2003
- Naltrexone in the Treatment of Alcohol DependenceNew England Journal of Medicine, 2001